Countermeasure and therapeutic: A(1–7) to treat acute respiratory distress syndrome due to COVID-19 infection. (November 2020)

• Record Type: Journal Article
• Authors: Soto, Maira; diZerega, Gere; Rodgers, Kathleen E
• Is Part Of: Journal of the renin-angiotensin-aldosterone system. Volume 21:Number 4(2020)
• Publication Date: 2020-11
• Subjects: COVID -- ARDS -- respiratory infection -- angiotensin (1–7) -- ACE2; Renin-angiotensin system -- Periodicals; 616.132
• DOI: 10.1177/1470320320972018
• Languages: English
• ISSNs: 1470-3203

Abstract

In the wake of the COVID-19 pandemic it has become clear that there is a need for therapies that are capable of reducing damage caused to patients from infections. Infections that induce Acute Respiratory Distress Syndrome (ARDS) are especially devastating because lung damage is so critical and difficult to manage. Angiotensin (1–7) [A(1–7)] has already been shown to protect pulmonary health and architecture in various models of disease. There is also evidence that A(1–7) can modulate immune function and protect various organs (lung, kidney, and heart) from oxidative damage and inflammation. Here we focus on making a case for the development of novel therapies that target the protective arm of the Renin Angiotensin System (RAS).